A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Incyte Corp stock. As of the latest transaction made, Bridgewater Associates, LP holds 366,612 shares of INCY stock, worth $21.2 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
366,612
Previous 368,034 0.39%
Holding current value
$21.2 Million
Previous $23.1 Million 9.62%
% of portfolio
0.11%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$56.55 - $66.59 $80,414 - $94,690
-1,422 Reduced 0.39%
366,612 $20.9 Million
Q4 2023

Feb 14, 2024

SELL
$52.16 - $64.19 $112,926 - $138,971
-2,165 Reduced 0.58%
368,034 $23.1 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $3.03 Million - $3.46 Million
52,454 Added 16.51%
370,199 $21.4 Million
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $2.51 Million - $3.11 Million
41,234 Added 14.91%
317,745 $19.8 Million
Q1 2023

May 12, 2023

BUY
$70.23 - $86.01 $356,066 - $436,070
5,070 Added 1.87%
276,511 $20 Million
Q4 2022

Feb 13, 2023

SELL
$67.18 - $84.11 $4.89 Million - $6.12 Million
-72,810 Reduced 21.15%
271,441 $21.8 Million
Q3 2022

Nov 10, 2022

SELL
$66.18 - $82.86 $3.09 Million - $3.87 Million
-46,692 Reduced 11.94%
344,251 $22.9 Million
Q2 2022

Aug 11, 2022

BUY
$66.18 - $83.18 $22.5 Million - $28.3 Million
340,133 Added 669.42%
390,943 $29.7 Million
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $1.9 Million - $2.29 Million
28,716 Added 129.97%
50,810 $4.04 Million
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $1.02 Million - $1.19 Million
16,047 Added 265.37%
22,094 $1.62 Million
Q3 2021

Nov 12, 2021

SELL
$68.67 - $84.02 $1.52 Million - $1.87 Million
-22,201 Reduced 78.59%
6,047 $416,000
Q2 2021

Aug 13, 2021

BUY
$79.87 - $87.53 $2.26 Million - $2.47 Million
28,248 New
28,248 $2.38 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $12.9B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.